Posts

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy. Medscape Medical News source https://www.medscape.com/viewarticle/talquetamab-combinations-show-survival-benefit-r-r-myeloma-2026a1000k6r?src=rss

Alcohol-Induced Deaths: Australian Experts Call for Support

Deaths from alcohol show no sign of declining, and some experts are calling for stronger regulation of alcohol advertising and more specialist services to meet demand. Medscape News Australia source https://www.medscape.com/viewarticle/alcohol-induced-deaths-australian-experts-call-support-2026a1000jz0?src=rss

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels. Medscape Medical News source https://www.medscape.com/viewarticle/encaleret-shows-rapid-response-autosomal-dominant-2026a1000jyu?src=rss

Urticaria Is Often a Team Sport for Derms and Allergists

Chronic urticaria is occasionally challenging, but dermatologists and allergists can help each other as well as the patient by combining their unique skills in difficult cases. Medscape Medical News source https://www.medscape.com/viewarticle/challenging-urticaria-often-team-sport-dermatologists-and-2026a1000jyq?src=rss

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study. Medscape Medical News source https://www.medscape.com/viewarticle/testosterone-prescribing-often-ignores-guidelines-2026a1000jym?src=rss

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements. Medscape Medical News source https://www.medscape.com/viewarticle/phase-3-palopegteriparatide-results-show-sustained-benefits-2026a1000jyi?src=rss